Difference between revisions of "Epratuzumab (LymphoCide)"

Revision as of 17:45, 5 August 2019

Anti-CD22 antibody

Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article

Revision as of 18:03, 3 February 2019 (view source) Warner-admin (talk \| contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") ← Older edit	Revision as of 17:45, 5 August 2019 (view source) Jwarner (talk \| contribs) m (Jwarner moved page Epratuzumab (humanised anti-CD22 antibody) to Epratuzumab (LymphoCide): brand name available) Newer edit →
(No difference)